Study on NGM707 Alone and with Pembrolizumab for Advanced or Metastatic Solid Tumors

Sponsor: NGM Biopharmaceuticals, Inc

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT04913337

Provider View

This clinical trial is testing a new drug, NGM707, both by itself and in combination with another drug, Pembrolizumab, to see if it can help treat advanced or metastatic solid tumors in patients who have not responded to other treatments.

Patient Parameters

Program Overview

The purpose of this study is to evaluate the effectiveness and safety of a new drug called NGM707, used alone or together with Pembrolizumab, in treating patients with advanced or metastatic solid tumors. These are cancers that have spread to other parts of the body and have not responded to standard treatments.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of advanced or metastatic solid tumor cancer.
  • Have tried all available treatments that are known to help with their type of cancer, but the cancer has either not responded or the patient could not tolerate the treatments.
  • Have good bone marrow, kidney, and liver function based on medical tests.
  • Be in good overall health with a performance status score of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
  • Have recovered from any side effects of previous treatments to a mild level or to the level they were before treatment, except for side effects that are not considered a safety risk by the study doctor.

Exclusion Criteria

  • Have previously received treatments that target ILT2 and/or ILT4 or HLA-G.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.